Topic Archives: Hyperion

Saving Jack Kerouac

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] His tidily rhyming names perhaps destined him for fame. While Jack Kerouac’s work and popularity were before my time, his cultural and literary restlessness assure him […]

Comments

  • What's with Hyperion, anyway? I subscribed to their Elite Options Trader and can't get an answer to their phone . Do t...

  • Dr. KSS, MD PhD

    Glenn: I agree with you. It does appear underpriced. I like the drug, predict clinical success, and its sole competition...

  • Dr. KSS, MD PhD

    Bradley, yes, aware. That has functionally cratered Ocera shares and here they are very cheap. They may have enough cap...

  • Dr. KSS, MD PhD

    David B: Ocera Therapeutics (OCRX) is one that has come up before here, for its iv drug ornithine phenylacetate for cirr...

  • Myron Martin, Junior Mining Columnist

    Jim: Your biggest mistake was not reading the fine print, when a promotion is being paid for by 3rd parties the chances ...

  • karmaswimswami

    We discussed Ocera Therapeutics a ways back, developing ornithine phenylacetate for portosystemic encephalopathy. Looks ...

  • Myron Martin

    It is indeed sad to see men who were once creditable analysts (warts and all) succumb to the easy money of paid promotio...

  • This is a great newsletter, overall. I have used it for two months now and it has been paying off quite nicely. Though...

  • I am subscribed to Penny Stock Breakouts as well as another newsletter by the same company (hyperion) and both products ...

  • Quick Strike Trader Hyperion Financial I think we all may have seen the top forming. It was too good to be true. The...

  • I've had this one for almost a year now. Cheap enough and I think they got lucky on HGSI because nothing sense has done...

  • Hyperion Financial, Pennystock Breakout this newsletter is undervalued at $49.00 annually for the returns I'm getting...

  • This review is for Hyperion Financial Sector ETF, editor Cory Williams. I have submitted to this report. In my view it s...

  • CURRENCY OPTIONS INSIDER / BRIAN T. MIKES / Hyperion Ok, so I've recently starting trading options and received Brian...

  • thanx gumshoe i'm a little leary of china. hsu loves it but it seems their bad debt problems may be worse than ours whe...

  • does anybody have a line on the chinese company that is the most direct investment on the pebble reactor? also the south...

  • Mr. Hsu should have written about magical unicorns, since they are as real as the "Straits of Ormez." Cindy, people t...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch